---
title: "Weekly Recap | WuXi Biologics +2.2%, a choppy climb"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/300852977.md"
description: "WuXi Biologics (WXXWY) closed the week at $13.95, up 2.2%. The S&P 500 slipped 0.27% over the same stretch, leaving the ADR about 2.47 percentage points ahead. It was a choppy week: the name dipped to $13.10 early on Monday, steadied on light volume on Tuesday, pushed to $14.30 on Wednesday, held near that level on Thursday, then pulled back within a $13.80 to $14.44 range on Friday. Price still sits above the 20-day average of $13.10 and the 60-day average of $11.78."
datetime: "2026-10-03T08:05:38.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/300852977.md)
  - [en](https://longbridge.com/en/news/300852977.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/300852977.md)
generator: "portal-rs"
---

# Weekly Recap | WuXi Biologics +2.2%, a choppy climb

## The Week

WuXi Biologics (WXXWY) closed the week at $13.95, up 2.2%. The S&P 500 slipped 0.27% over the same stretch, leaving the ADR about 2.47 percentage points ahead. It was a choppy week: the name dipped to $13.10 early on Monday, steadied on light volume on Tuesday, pushed to $14.30 on Wednesday, held near that level on Thursday, then pulled back within a $13.80 to $14.44 range on Friday. Price still sits above the 20-day average of $13.10 and the 60-day average of $11.78. There was no major company news or earnings; the only item was a Monday note discussing the FDA inspection clearance. That made for a quiet week overall.

## The Week Ahead

The focus shifts to macro data. Monday brings the US S&P Global services PMI final (prior 58.7) and the ISM non-manufacturing PMI (prior 55.4, forecast 55). Tuesday has the trade balance and goods trade balance. Wednesday features EIA crude inventory data. With no scheduled earnings for WuXi Biologics, the direction will likely track OTC market liquidity and the broader biotech tape.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [WXXWY.US](https://longbridge.com/en/quote/WXXWY.US.md)

## Related News & Research

- [Will FDA Inspection Clearance Change WuXi Biologics Stock Narrative For WuXi Biologics (Cayman) (SEHK:2269)](https://longbridge.com/en/news/300317438.md)
- [Why Did WuXi Biologics (Cayman) (SEHK:2269) Move Today?](https://longbridge.com/en/news/300196354.md)
- [G Sachs Says WUXI BIO Commercialization Visibility Improves, Maintains Neutral Rating](https://longbridge.com/en/news/300098674.md)
- [Constellation Brands Stock Forecast: Beer Demand Faces a Key Q2 Earnings Test](https://longbridge.com/en/news/300859275.md)
- [If I Could Only Buy 1 Space Stock for the Next Decade, It Wouldn't Be SpaceX or Rocket Lab](https://longbridge.com/en/news/300850222.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**